304 related articles for article (PubMed ID: 22715896)
1. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract][Full Text] [Related]
2. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
[TBL] [Abstract][Full Text] [Related]
3. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM; Lyseng-Williamson KA; Frampton JE
BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
[TBL] [Abstract][Full Text] [Related]
4. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib for the treatment of medullary thyroid cancer.
Chau NG; Haddad RI
Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
8. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
Ton GN; Banaszynski ME; Kolesar JM
Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
11. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S; Bastholt L; Krause T; de la Fouchardiere C; Tennvall J; Awada A; Gómez JM; Bonichon F; Leenhardt L; Soufflet C; Licour M; Schlumberger MJ
Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib and the management of advanced medullary thyroid cancer.
Campbell MJ; Seib CD; Gosnell J
Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
16. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib therapy in medullary thyroid cancer.
Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
[TBL] [Abstract][Full Text] [Related]
18. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
19. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Thornton K; Kim G; Maher VE; Chattopadhyay S; Tang S; Moon YJ; Song P; Marathe A; Balakrishnan S; Zhu H; Garnett C; Liu Q; Booth B; Gehrke B; Dorsam R; Verbois L; Ghosh D; Wilson W; Duan J; Sarker H; Miksinski SP; Skarupa L; Ibrahim A; Justice R; Murgo A; Pazdur R
Clin Cancer Res; 2012 Jul; 18(14):3722-30. PubMed ID: 22665903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
